NY-ESO-1 (p157-165) HLA-A*02:01 CHO Cell Line

NY-ESO-1(p157-165) HLA-A*02:01 CHO Cell Line is a CHO-K1 cell line constitutively expressing the human NY-ESO-1 (New York esophageal squamous cell carcinoma 1) peptide 157-165, B2M (beta-2 microglobulin), and HLA (human leukocyte antigen)-A*02:01. This cell line was functionally validated in a co-culture assay with NY-ESO-1 TCR CD8+ NFAT Luciferase Reporter Jurkat cells (BPS Bioscience #78769). Figure 1: Illustration of the co-culture assay used for validation of NY-ESO-1(p157-165) HLA-A*02:01 CHO Cell Line. Human Leukocyte Antigen-A (HLA-A) is an MHC-I (major histocompatibility complex) heavy chain receptor, composed of HLA-A and beta2-microglobulin (B2M). There are over 200 genes encoding HLA variants and this variability plays a critical role in adaptive immunity. HLA-A*02 is one of the most common class I types. HLA class I molecules are involved in presenting peptides that are typically between 8 to 11 amino acids. HLA-A*02:01 can bind 15-mer peptides, which can then be recognized by T cells. Studies in SCLC (small cell lung cancer) patients have shown that an ATAD2 (ATPase family AAA domain-containing protein 2) immunopeptide can be used in HLA-A*02-01-restricted patients with high reactivity. NY-ESO-1 (New York esophageal squamous cell carcinoma 1, also known as Cancer/testis antigen 1, or CTAG1B), is an important tumorigenic marker present in malignant cells. Normally expressed only in embryonic testis, this highly immunogenic protein is not usually found in normal tissues, but is re-expressed in multiple myeloma, non-small cell lung carcinoma, and breast and ovarian cancer, making it a promising candidate antigen for cancer immunotherapy. Several NY-ESO-1-directed therapies are being developed including cancer vaccines, anti-NY-ESO-1 adoptive cell therapy, alone or in combination with checkpoint inhibitors.